Search Results - "Jehl, V."

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up by Lebwohl, M., Deodhar, A., Griffiths, C.E.M., Menter, M.A., Poddubnyy, D., Bao, W., Jehl, V., Marfo, K., Primatesta, P., Shete, A., Trivedi, V., Mease, P.J.

“…Summary Background Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long‐term robust studies. Objectives To assess the…”
Get full text

Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer by Besse, B., Leighl, N., Bennouna, J., Papadimitrakopoulou, V.A., Blais, N., Traynor, A.M., Soria, J.-C., Gogov, S., Miller, N., Jehl, V., Johnson, B.E.

“…Preclinical data suggest combining a mammalian target of rapamycin inhibitor with erlotinib could provide synergistic antitumor effects in advanced…”
Get full text

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study by Piedbois, P., Serin, D., Priou, F., Laplaige, P., Greget, S., Angellier, E., Teissier, E., Berdah, J.-F., Fabbro, M., Valenza, B., Herait, P., Jehl, V., Buyse, M.

“…Background: Adding a taxane to anthracycline-based adjuvant chemotherapy prolongs survival in node-positive patients but optimal dose and schedule remain…”
Get full text

6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET) by Ricci, S, Ruszniewski, P, Tomasetti, P, Jehl, V, Saletan, S, Yao, J.C, Pavel, M

Get full text

9174 Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC) by Soria, J.C, Bennouna, J, Leighl, N, Khuri, F, Traynor, A.M, Johnson, B, Kay, A, Blais, N, Jehl, V, Papadimitrakopoulou, V

Get full text

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2 by Yao, J. C., Ricci, S., Winkler, R. E., Jehl, V., Pavel, M. E.

“…Abstract only…”
Get full text

Using Bayesian proof-of-concept criteria to design randomized phase II oncology trials stratified by biomarker status by Appanna, K. V., Zuber, E. P. H., Jehl, V., Zhang, Y., Wang, Y., racine-Poon, A., Neuenschwander, B.

“…Abstract only…”
Get full text

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial by Anthony, L. B., Peeters, M., Hainsworth, J. D., Baudin, E., Hoersch, D., Klimovsky, J., Grouss, K., Jehl, V., Pavel, M. E., Yao, J. C.

“…Abstract only…”
Get full text

Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2) by Yao, J. C., Hainsworth, J. D., Baudin, E., Peeters, M., Hoersch, D., Anthony, L. B., Klimovsky, J., Grouss, K., Jehl, V., Pavel, M.

“…Abstract only 159 Background: Octreotide LAR has been the foundation of NET therapy; however, additional treatment options are needed. Everolimus, an oral…”
Get full text

Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC) by Leighl, N. B., Soria, J., Bennouna, J., Blais, N., Traynor, A. M., Papadimitrakopoulou, V., Klimovsky, J., Jappe, A., Jehl, V., Johnson, B. E.

“…Abstract only…”
Get full text